Autoantibodies in Vitiligo Patients Recognize Multiple Domains of the Melanin-Concentrating Hormone Receptor

Journal of Investigative Dermatology

Volumn 121, Issue 4, 2003, Pages 765-770

  Gottumukkala, Raju V S R K ^a   Waterman, Elizabeth A ^a   Herd, Laura M ^a   Gawkrodger, David J ^b   Watson, Philip F ^a   Weetman, Anthony P ^a   Kemp, E Helen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Autoantigen; Autoimmunity; B lymphocyte; Epitope mapping; Melanocyte

Indexed keywords

AMINO ACID; AUTOANTIBODY; COMPLEMENTARY DNA; HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR; METHIONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BINDING ASSAY; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; VITILIGO;

EID: 0141922039     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2003.12494.x     Document Type: Article

References (33)

1. Barakat S, Meyer O, Toterotot F, Youinou P, Briand JP, Kahn MF, Muller S: IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognise different epitopes in 60-kD SSA/Ro protein. Clin Exp Immunol 89:38-45, 1992
2. Cui J, Harning R, Henn M, Bystryn J-C: Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 98:162-165, 1992
3. Cui J, Arita Y, Bystryn J-C: Characterisation of vitiligo antigens. Pigment Cell Res 8:53-59, 1995
4. Gilhar A, Zelickson B, Ulman Y, Etzioni A: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105: 683-686, 1995
5. Harning R, Cui J, Bystryn J-C: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97:1078-1080, 1991
6. Hedstrand H, Ekwall O, Olsson MJ, et al: The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem 276:35390-35395, 2001
7. Hoedemaekers AC, Van Breda Vriesman PJ, De Baets MH: Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 16:341-354, 1997
8. Hoogduijn MJ, Ancans J, Suzuki I, Estdale S, Thody AJ: Melanin-concentrating hormone and its receptor are expressed and functional in human skin. Biochem Biophys Res Commun 296:698-701, 2002
9. 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109:69-73, 1997
10. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP: Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 139:798-805, 1998a
11. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP: Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: A sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 114:333-338, 1998b
12. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP: Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo. J Invest Dermatol 113:267-271, 1999
13. Kemp EH, Waterman EA, Hawes BE, et al: The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 109:923-930, 2002
14. Kolakowski JLK, Jung BP, Nguyen T, et al: Characterisation of a human gene related to genes encoding somatostatin receptors. FEBS Lett 398:253-258, 1996
15. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E: Autoantibodies in insulin-dependent diabetes recognise distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157:2707-42711, 1996
16. Lang KS, Caroli CC, Muhm A, et al: HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 116:891-897, 2001
17. MacDonald D, Murgolo N, Zhang R, Durkin JP, Yao X, Strader CD, Graziano MP: Molecular characterisation of the melanin-concentrating hormone/receptor complex: Identification of critical residues involved in binding and activation. Mol Pharmacol 58:217-225, 2000
18. Morgenthaler NG, Hodak K, Seissler J, et al: Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: A comparison to radioreceptor assay and thyroid stimulating bioassay. Thyroid 9:467-475, 1999
19. Naserke HE, Ziegler AG, Lampasona V, Bonafacio E: Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 161:6963-6969, 1998
20. Naughton GK, Eisinger M, Bystryn J-C: Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:245-251, 1983
21. Naughton GK, Reggiardo MD, Bystryn J-C: Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 15:978-981, 1986
22. Norris DA, Kissinger RM, Naughton GK, Bystryn J-C: Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90:783-789, 1988
23. Ochi Y, DeGroot LJ: Vitiligo in Graves' disease. Ann Intern Med 71:935-940, 1969
24. Ogg GS, Dunbar PR, Romero P, Chen J-L, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-1208, 1998
25. Okamoto T, Irie RF, Fujii S, Huang SKS, Nizze AJ, Morton DL, Hoon DSB: Antityrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-1039, 1998
26. Palermo B, Campanelli R, Garbelli S, et al: Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117:326-332, 2001
27. Parker JMR, Guo D, Hodges RS: New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425-5432, 1986
28. Petterson I: Methods of epitope mapping. Mol Biol Rep 16:149-153, 1992
29. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989
30. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N: The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049-1052, 1994
31. Syren K, Lindsay L, Stoehrer B, Jury K, Lühder F, Baekkeskov S, Richter W: Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 157:5208-5214, 1996
32. Wucherpfennig KW: Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108:1097-1104, 2001
33. Zanelli E, Henry M, Malthiery Y: Use of recombinant epitopes to study the heterogeneous nature of the autoantibodies against thyroid peroxidase in autoimmune thyroid disease. Clin Exp Immunol 87:80-86, 1992